A few key publications report on the frequency of skin disorders in paediatric organ transplant recipients in Southern and Central Europe presenting cumulative incidences. We aimed to estimate frequencies of skin disorders both as cumulative incidences and prevalence data, and describe skin problems in paediatric renal transplant recipients in a Norwegian renal transplant population. Clinical examination and review of post-transplant skin diseases were conducted in 70 patients having performed renal transplantation before the age of 16 in the period 1983–2006. Viral warts were a common and persistent problem, whereas bacterial and fungal infections in the skin were few. Drug-related skin disorders were rather frequent, but usually reversible on dose reduction or change of medication. Pre-malignant and malignant skin disorders appeared only in patients >30 years of age. Relatively high cumulative incidences and low prevalence data of most skin disorders were found in the examined patient cohort. Key words: children; immunosuppression; organ transplant recipients; skin disorders.

The prevalence of skin disorders in Norwegian paediatric renal transplant recipients

Jan Cezary SITEK1, Trine TANGERAAS2, Anna BJERRE2 and Per HELSING1
Departments of 1Dermatology, and 2Pediatrics, Oslo University Hospital, Oslo, Norway

Accepted Aug 18, 2013; Epub ahead of print Nov 28, 2013


The transplant population is steadily increasing as a result of both surgical and medical developments. Long-term morbidity and mortality of patients and grafts are improving, reflecting effective immunosuppressive regimens. The drawback of effective immunosuppression is an increased risk of infections (1) and cancer (2), in particular skin malignancies (3). This risk is increasing with time after transplantation (3, 4), putting paediatric organ transplant recipients (OTRs) at special risk. In addition, immunosuppressive medication may predispose to other skin problems as acne, hypertrichosis and gingival hyperplasia in paediatric OTRs (5, 6).

During the last 10 years, only 2 studies have described skin disorders in children with organ transplants; both studies describing the cumulative incidences (5, 6). The study by Euuvard et al. (5) describes skin diseases in 145 patients (117 renal transplant recipients (RTRs)) transplanted in childhood with a follow-up period up to 10 years. The other paper by Fortina et al. (6) reports 217 patients (168 RTRs) aged <18 years at transplantation followed up to 28 years after transplantation.

During the period 1970–2006, 251 renal transplantations were performed in 178 children in Norway. Children born after 1983 were invited to participate in a study, aiming to investigate long-term patient and graft survival (7), as well as cardiorespiratory fitness (8) and mental health (9) in paediatric RTRs. A part of the study was planned to describe the prevalence and cumulative incidences of skin disorders in this population. The Department of Dermatology at Oslo University Hospital keeps a specific outpatient clinic for OTRs. Our impression is that the paediatric OTR population runs a lower risk of skin disorders than previously reported (5, 6). This study aims at giving prevalence data, as well as cumulative incidences, to better describe the magnitude of skin problems in the paediatric RTR population.

MATERIALS AND METHODS

All patients were recruited from the HENT study (ClinicalTrials.gov NCT01008306). The patients were identified through the Norwegian Renal Registry, having their first renal transplant before 16 years of age in the period 1983–2006. Living recipients were invited to participate in a cross-sectional study involving a 2-day comprehensive medical investigational program, including an examination by a dermatologist.

A total of 70 patients were enrolled from May 2008 to June 2009, 68 patients having performed renal transplantation only and 2 patients having performed combined renal and liver transplantation. Seventy-three percent of the patients had received a kidney from a living donor. In the period 1983–1999, paediatric RTRs were treated with cyclosporine, either in conjunction with steroids, or as a triple regimen including azathioprine. From the year 2000, induction therapy with basiliximab was introduced, and the mainstay treatment was corticosteroids and inhibitors of calcineurin (tacrolimus after 2002).

Participants were interviewed by a nurse specialised in dermatology, registering previous skin disorders after transplantation in an extensive, structured questionnaire. Medical records and the questionnaire were reviewed by the dermatologist, adding current skin disorders after a total skin examination. Children <18 years and some older individuals were accompanied by a parent. Prior to study inclusion informed consent was obtained from participants if older than 16 years, or their parents younger than 16 years of age. All frequency data are presented as numbers and percentages.

The study protocol was approved by the Regional Ethical Committee and the study conducted in accordance with the Helsinki declaration.
RESULTS

Seventy patients were included, 61% male, 38 < 19 years of age, with mean age at the time of investigation of 20.5 (3–41) years. Mean age at the time of transplantation was 8.9 (1–16) years; mean follow-up time for the group was 11.6 (2–29) years. Fifty-three percent of the participants were currently on a triple regimen, while the remaining patients were treated with 1 or 2 immunosuppressants (Table I).

Data are presented both in terms of self-reported cumulative incidences (questionnaire and interview) and prevalence data (clinical examination) (Table II).

Infectious diseases

Skin infections were the dominant disorder, both in terms of cumulative incidence and prevalence of disease. Six patients (8.6%) reported having no previous or current viral, fungal or bacterial skin disease. Current skin infection was present in 54.2% of the patients.

Fifty-two patients (74.3%) reported former or chronic problems with warts after transplantation (Fig. 1A). A cumulative incidence of 11.4% was observed for both condylomas and mollusci, condylomas being more prevalent in patients > 20 years of age (Table II).

Drug induced skin disorders

Drug induced skin disorders were frequent and mainly attributed to the use of steroids and cyclosporine (Table II). Striae distensa (24.3%) and acne (18.6%) were the most frequent disorders discovered on examination, mainly attributed to the use of prednisolone. Cushingoid facies was found in 3 patients (4.3%). Hypertrichosis and gingival hyperplasia are common side effects of cyclosporine, and rather frequently reported as a serious complication.

Table I. Patient characteristics of 70 paediatric renal transplant recipients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All patients</th>
<th>≤ 18 years</th>
<th>&gt; 18 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at first transplantation</td>
<td>8.9 (± 4.8)</td>
<td>8.1 (± 0.6)</td>
<td>11.7 (± 3.6)</td>
</tr>
<tr>
<td>Age of allograft</td>
<td>0.8–15.9</td>
<td>0.8–15.7</td>
<td>0.8–15.9</td>
</tr>
<tr>
<td>Age at investigation</td>
<td>11.6 (± 7.8)</td>
<td>6.0 (± 3.6)</td>
<td>18.1 (± 6.3)</td>
</tr>
<tr>
<td>Age in years, mean age (95% confidence interval).</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table II. Cumulative incidence (CumI) and point prevalence (PP) of skin disorders in paediatric renal transplant recipients

<table>
<thead>
<tr>
<th>Infectious diseases</th>
<th>CumI, n = 70</th>
<th>PP, n = 70</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral warts</td>
<td>74.3 (52)</td>
<td>48.6 (34)</td>
</tr>
<tr>
<td>Condylomas</td>
<td>11.4 (8)</td>
<td>5.7 (4)</td>
</tr>
<tr>
<td>Mollusci</td>
<td>11.4 (8)</td>
<td>5.7 (4)</td>
</tr>
<tr>
<td>Herpes simplex virus infections</td>
<td>30 (21)</td>
<td>2.9 (2)</td>
</tr>
<tr>
<td>Varicella zoster virus infection</td>
<td>12.9 (9)</td>
<td>0</td>
</tr>
<tr>
<td>Pityriasis versicolor</td>
<td>2.9 (2)</td>
<td>0</td>
</tr>
<tr>
<td>Dermatophyte infections</td>
<td>8.6 (6)</td>
<td>0</td>
</tr>
<tr>
<td>Candidal infection (oropharyngeal)</td>
<td>2.9 (2)</td>
<td>0</td>
</tr>
<tr>
<td>Bacterial skin infections</td>
<td>18.6 (13)</td>
<td>1.4 (1)</td>
</tr>
</tbody>
</table>

Drug induced

Striae distensa not applicable 24.3 (17) |
Sebaceous gland hyperplasia not applicable 8.6 (6) |
Acne not applicable 18.6 (13) |
Cushingoid facies not applicable 4.3 (3) |
Hypertrichosis, serious 20 (14) 1.4 (1) |
Gingival hyperplasia, serious 7.1 (5) 0 |
Precancerous and cancer lesions (skin) |
Actinic keratosis 4.3 (3) 1.4 (1) |
Keratoacanthoma 1.4 (1) 0 |
Carcinoma in situ 1.4 (1) 0 |
Basal cell carcinoma 1.4 (1) 0 |
Squamous cell carcinoma/malignant melanoma 0 0 |

Other |
Naevi count >50 not applicable 15.7 (11) |
Eczema (atopic, irritative) 22.9 (16) |
Xerosis symptomatic 14.3 (10) |
Skin disorders in paediatric renal transplant recipients

**Skin precancerous/cancer lesions**

Precancerous and cancer lesions were reported in 5 patients (7.1%), all being >30 years of age.

Three patients (4.3%) had been treated for actinic keratoses, one for keratoacanthoma and one for carcinoma in situ, all histology proven. One of these had also been treated for 5 basal cell carcinomas. Stucco-like keratoses were observed in all 5 patients. No patients had a history of squamous cell carcinoma, melanoma or other skin associated cancers (Table II).

**Miscellaneous**

Other skin complaints were registered, being mostly symptomatic dry skin (14.3%) and eczema (22.9%). Approximately half of the subjects (49%) had a total naevi count less than 25 (Table II).

Less frequent findings included pitted keratolysis, trichodysplasia spinulosa (Fig. 1C) and acral acantheosis nigricans.

**DISCUSSION**

Viral warts were the predominant skin disorder, with high reported cumulative incidence and prevalence on examination. Other rather frequent current disorders were acne and striae distensa. However, our results show that most paediatric RTRs had relatively few skin complaints and few current disorders, indicating that most conditions are manageable.

The present study differs on several aspects from the previous studies. Our study population of 70 RTRs is smaller than the studies by Euvrard et al. (5) \( n = 145 \) and Fortina et al. (6) \( n = 217 \). Our follow-up time after transplantation is longer, with mean age of allograft being 11.6 years, as compared to 6.6 years and 1 month–10 years in the studies by Fortina et al. and Euvrard et al., respectively. In addition, these studies only reported on cumulative incidences.

Viral warts were quite frequent, showing cumulative incidence of 74.2%. Viral warts are relatively common also among Scandinavian secondary school pupils. Prevalences of 20% have been reported among adolescents (10) as compared to a prevalence of 45% in our study population below 18 years of age. Warts were predominantly located on hands and feet, with increasing involvement of hands with age. Both high cumulative incidence and prevalence show that viral warts in the transplant population are difficult to treat. Most patients had tried different treatment strategies, including repetitive liquid nitrogen cryotherapy, imiquimode under occlusion and laser therapy, however with a low success rate. Onset of viral warts in formerly naïve patients was 1.6 years after transplantation (Table III). In patients ≤18 years of age, absence of viral wart infection was exclusively seen in patients following the mono or duo immunosuppressive treatment protocol (Table IV). These observations may indicate that intensity of immunosuppressive therapy is of importance for the development of viral warts.

The occurrence of both mollusci and condylomas was also higher than previously reported (5, 6). Both conditions were actively searched for in our study and may easily be overlooked by routine examination without specifically addressing the condition. Mollusci debuted primarily during adolescence whereas condylomas typically occurred in adult age (Table III). Similarly to viral warts both conditions seem hard to eradicate, as half of patients reporting previous infection presented current disease, which may be due to immunosuppression.

Nearly 1/3 of the patients reported having suffered from herpes simplex infection, with median onset 1.7 years after transplantation. Herpes simplex virus (HSV) is however also common in the general population with a British study reporting a 17–27% HSV-1 prevalence in children aged 1–14 years (11). Among the 8 naïve patients reporting varicella zoster infection, median onset was 5.7 years post-transplant, one patient experiencing multiple episodes (Table III).

Pityriasis versicolor was a frequent finding in previously referred studies, with cumulative incidences of 20.7% and 14.5%, respectively (5, 6). No patients in our cohort were diagnosed with ongoing fungal infection. A possible explanation could be different climate conditions (12).

Bacterial skin infections were rare in this cohort; impetigo and folliculitis being the most frequent complaints, but none experiencing recurrent episodes. Median onset was more than 10 years after transplantation (Table III).

A considerable part of the paediatric RTRs reported drug related skin manifestations on examination, which

<table>
<thead>
<tr>
<th>Skin disorders</th>
<th>Age (years) at debut</th>
<th>Age (years) of allograft at debut</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median</td>
<td>Median</td>
</tr>
<tr>
<td>Viral warts, ( n = 38 )</td>
<td>11.8</td>
<td>1.6</td>
</tr>
<tr>
<td>Herpes simplex virus infection, ( n = 15 )</td>
<td>13</td>
<td>1.7</td>
</tr>
<tr>
<td>Striae distensa, ( n = 13 )</td>
<td>14</td>
<td>1.8</td>
</tr>
<tr>
<td>Condylomas, ( n = 8 )</td>
<td>22</td>
<td>10</td>
</tr>
<tr>
<td>Mollusci, ( n = 8 )</td>
<td>12.5</td>
<td>5.8</td>
</tr>
<tr>
<td>Varicella zoster virus infection, ( n = 8 )</td>
<td>18</td>
<td>5.7</td>
</tr>
<tr>
<td>Bacterial infection, ( n = 6 )</td>
<td>22.5</td>
<td>10.9</td>
</tr>
<tr>
<td>Sebaceous gland hyperplasia, ( n = 4 )</td>
<td>31</td>
<td>18.8</td>
</tr>
<tr>
<td>Dermatophyte infection, ( n = 4 )</td>
<td>12.5</td>
<td>2.5</td>
</tr>
<tr>
<td>Actinic keratosis, ( n = 3 )</td>
<td>30</td>
<td>18</td>
</tr>
<tr>
<td>Oropharyngeal candida, ( n = 2 )</td>
<td>25</td>
<td>13</td>
</tr>
<tr>
<td>Pityriasis versicolor, ( n = 2 )</td>
<td>15.5</td>
<td>3.1</td>
</tr>
<tr>
<td>Basal cell carcinoma, ( n = 1 )</td>
<td>32</td>
<td>20</td>
</tr>
<tr>
<td>Carcinoma in situ, ( n = 1 )</td>
<td>36</td>
<td>24</td>
</tr>
</tbody>
</table>

**Table III. Debut of skin diseases after renal transplantation in disease-naive paediatric renal transplant recipients**
is in accordance with previous studies (5, 6, 13, 14). Striae distensa and acne, considered side effects of steroids, were the dominant findings. Striae was found in almost 1/4 of the patients. Some patients reported onset of striae before transplantation, frequently attributed to high-dose corticosteroid treatment due to their primary kidney disease. Interestingly, a similar prevalence value (27%) was found in healthy Scandinavian adolescents (10), indicating that age and puberty may well be as important as corticosteroid treatment for the development of striae in this age group. Nearly 1/5 of the patients had acne on examination. A discrimination between drug and adolescence-associated acne was not performed, which makes comparison with previous studies difficult.

Current cyclosporine-related skin disorders were few. A rather high frequency of hypertrichosis and serious gingival hyperplasia was reported, but these conditions were reversible on dose reduction or discontinuation of cyclosporine, and only one patient had serious hypertrichosis on examination. Sebaceous gland hyperplasia was observed exclusively among adult patients of both sexes, with median onset 18.8 years after transplantation (Table III).

Development of pre-malignant and malignant skin lesions is a major concern in the transplant population, and should be of special concern in the paediatric population, since risk of precancerous lesions and cancer is related to time after transplantation and total immunosuppressive load (3, 4). We found precancerous and cancerous lesions only in adult patients with onset when they were between 30–40 years of age (Table III). Whether these observations are higher than expected is unclear as standardised incidence ratios are not obtainable due to lack of national age-specific incidence rates for actinic keratosis, basal cell carcinoma and carcinoma in situ. Longer follow-up time may explain the higher frequency of these lesions in our cohort, as may constitutional differences. Our study population most likely has lighter skin phototypes compared to participants in the South European studies, which increases the risk of skin cancers. However, the limited number of patients restricts conclusions. The patient with 5 basal cell carcinomas has been examined for Gorlin-Goltz syndrome, presenting no other clinical signs of this disease.

Limitations to this study are the rather few patients compared to previous studies (5, 6), and that data on cumulative incidence is largely based on self-report or comparent information. Further, our prevalence data are based on a sample of the total paediatric RTR population and could be subject to sampling bias.

In conclusion, our study adds important information on skin disorders in paediatric RTRs. Current status show that prevalence of skin disorders is generally low, with an exception for viral warts and certain steroid-induced skin manifestations. The development of pre-malignant and malignant skin lesions in adult age is still a major concern, and preventive strategies should be addressed at follow-up.

ACKNOWLEDGEMENTS

The authors thank dr Cato Mørk for his contribution during the early phases of the study. We also thank nurses Liv Irene Eikefjord and Anita Jacobsen for their contribution to collecting patient data.

REFERENCES